Cargando…
Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
INTRODUCTION: The long-term benefit–risk profiles of licensed and investigational treatments for moderate-to-severe plaque psoriasis have not been fully characterized. METHODS: Randomized controlled trials (RCTs) of licensed and investigational treatments for moderate-to-severe plaque psoriasis were...
Autores principales: | Armstrong, April W., Soliman, Ahmed M., Betts, Keith A., Wang, Yan, Gao, Yawen, Stakias, Vassilis, Puig, Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776931/ https://www.ncbi.nlm.nih.gov/pubmed/34862951 http://dx.doi.org/10.1007/s13555-021-00647-0 |
Ejemplares similares
-
A Response to: Letter to the Editor Regarding Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
por: Armstrong, April W., et al.
Publicado: (2022) -
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
por: Armstrong, April W., et al.
Publicado: (2021) -
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
por: Armstrong, April W., et al.
Publicado: (2023) -
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
por: Armstrong, April W., et al.
Publicado: (2023) -
Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials
por: Strober, B.E., et al.
Publicado: (2018)